A Study of iMSC for the Prevention of Acute Graft-versus-host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Exclusion Criteria

• •Serious organ dysfunction such as organ failure after allogeneic HSCT;
• •Received more than once HSCT (including autologous transplants);
• •Positive for Hepatitis B Surface Antigen (HBsAg) or Hepatitis B Core Antibody (HBcAb) and have Hepatitis B Virus (HBV) DNA titers above the normal range ; positive for Hepatitis C Virus (HCV) antibodies and have positive peripheral blood HCV RNA; positive for Human Immunodeficiency Virus (HIV) antibodies; positive for syphilis;
• •Subjects with severe hepatic veno-occlusive disease or sinus veno-occlusive syndrome;
• •Primary malignant hematologic disease was not remission;
• •Within 6 months prior to enrollment, subjects had other diseases or their physiological conditions may interfere the study results, or had life-threatening complications;
• •Those who are suffering mental or neurological illnesses, unable to express will correctly;
• •Those with active malignant solid tumors within 5 years prior to participation in this study, with the exception of radically treated cervical cancer, in situ limited prostate cancer, and nonmelanoma skin cancer;
• •Subjects known to be potentially allergic or highly sensitized to the cell therapy in the study protocol;
• •Have participated or are participating in another clinical trial within one month prior to enrollment;
• •Those who are judged by the investigator to be unsuitable for participation in this clinical trial.